ClinicalTrials.gg
CompletedNCT07546448Updated Nov 18, 2026

Serum Electrolytes and Contrast-Induced Nephropathy in Acute Ischemic Stroke Patients Undergoing Endovascular Treatment

An observational study in Acute Ischemic Stroke, Contrast-induced Nephropathy and Acute Kidney Injury, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Observational

How we know

Updated Nov 18, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,760
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Ischemic Stroke with a site in Turkey — 12 open to participants now, 16 under way, 1 of them phase 3. Ischemic Stroke · Turkey.

Enrollment
Largest of 16
4,760 · median 90
Started
2026
with 7 others
Observational
16 of 54
3 open now
Registered
50th of 54
by date
Lead sponsor
2 of 54
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

Among the 54 studies in Ischemic Stroke with a site in Turkey, this one has the largest enrollment of the 16 observational ones that give a count, is one of 8 that started in 2026, is one of 16 observational ones, and was the 50th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 54 studies in Ischemic Stroke with a site in Turkey are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Ischemic Stroke with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).

Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.

In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.

The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.

Read the detailed description

This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.

Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.

Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.

In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.

Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.

The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.

03

Conditions studied

  • Acute Ischemic Stroke
  • Contrast-induced Nephropathy
  • Acute Kidney Injury

Keywords

  • Acute Ischemic Stroke
  • Contrast-Induced Acute Kidney Injury
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.

The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Patients diagnosed with acute ischemic stroke
  • Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
  • Patients with a baseline NIHSS score of 6 or higher
  • Patients who received iodinated contrast medium during the endovascular procedure
  • Patients managed under general anesthesia
  • Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
  • APACHE score greater than 25 at the time of the procedure
  • Known allergy or to iodinated contrast media
  • Exposure to iodinated contrast media within the previous 2 weeks
  • Use of nephrotoxic medications within the previous 2 weeks
  • History of myocardial infarction or previous stroke
  • Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
  • Systemic use at the time of the procedure
  • Incomplete medical records or missing laboratory data required for evaluation of CI-AKI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,760 participants (actual)
Patient registry
No

Groups and cohorts

  • CI-AKI Group

    Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.

    Other: No intervention (observational cohort study)

  • Non-CI-AKI Group

    Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.

    Other: No intervention (observational cohort study)

Interventions

  • OtherNo intervention (observational cohort study)

    No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

06

What researchers measure

Primary outcomes

  1. Incidence of contrast-induced acute kidney injury (CI-AKI)

    CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.

    Time frame: Within 48-72 hours after contrast exposure

Secondary outcomes

  1. 90-day mortality

    All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI).

    Time frame: Within 90 days after endovascular therapy

  2. Dialysis dependency in patients with CI-AKI

    Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI)

    Time frame: Within 90 days after endovascular therapy

  3. Change in serum creatinine

    Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure.

    Time frame: Baseline to 48-72 hours after endovascular therapy

  4. Association between serum electrolyte levels and CI-AKI

    Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury.

    Time frame: Baseline (pre-procedural measurements)

  5. Length of hospital stay

    Total duration of hospitalization in days, compared between patients with and without CI-AKI.

    Time frame: Within 90 days after endovascular therapy

  6. Inflammatory markers and CI-AKI relationship

    Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI.

    Time frame: Baseline (pre-procedural measurements)

  7. Change in estimated glomerular filtration rate (eGFR)

    Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure

    Time frame: Baseline to 48-72 hours after endovascular therapy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2026 to primary completion in Nov 2026, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → Nov 2026 and completion May 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 22, 2026
StartActual
Apr 23, 2026
Primary completionActual
Nov 10, 2026was May 2026
CompletionActual
Nov 11, 2026was May 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 18, 2026
Start date
Apr 20, 2026→Apr 23, 2026 (actual)
Nov 18, 2026
Primary completion
May 10, 2026→Nov 10, 2026 (actual)
Nov 18, 2026
Study completion
May 10, 2026→Nov 11, 2026 (actual)
Nov 18, 2026
Enrollment
250 (estimated)→4760 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Completed
    Start date Apr 20, 2026→Apr 23, 2026 (now actual)
    Primary completion May 10, 2026→Nov 10, 2026 (now actual)
    Study completion May 10, 2026→Nov 11, 2026 (now actual)
    Enrollment 250 (estimated)→4760 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546448
Lead sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Responsible party
Fatma Acil,MD (Principal Investigator, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital) — Principal investigator
First posted
Apr 22, 2026
Start date
Apr 23, 2026
Primary completion
Nov 10, 2026
Completion
Nov 11, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion